Guardant Health Ownership
| GH Stock | USD 32.65 1.67 5.39% |
Shares in Circulation | First Issued 2017-09-30 | Previous Quarter 122.4 M | Current Value 123.1 M | Avarage Shares Outstanding 98.1 M | Quarterly Volatility 14.6 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Guardant |
Guardant Stock Ownership Analysis
About 95.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 4.28. Guardant Health had not issued any dividends in recent years. Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company was incorporated in 2011 and is headquartered in Redwood City, California. Guardant Health operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 1373 people. To learn more about Guardant Health call Helmy Eltoukhy at 855 698 8887 or check out https://guardanthealth.com.Besides selling stocks to institutional investors, Guardant Health also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Guardant Health's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Guardant Health's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Guardant Health Quarterly Liabilities And Stockholders Equity |
|
Guardant Health Insider Trades History
About 5.0% of Guardant Health are currently held by insiders. Unlike Guardant Health's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Guardant Health's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Guardant Health's insider trades
Guardant Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Guardant Health is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Guardant Health backward and forwards among themselves. Guardant Health's institutional investor refers to the entity that pools money to purchase Guardant Health's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 2.8 M | Parkwood Llc | 2024-06-30 | 2.8 M | State Street Corp | 2024-06-30 | 2.8 M | Fuller & Thaler Asset Management Inc | 2024-09-30 | 2.2 M | Millennium Management Llc | 2024-06-30 | 2.1 M | Temasek Holdings Ltd. | 2024-09-30 | 2.1 M | Fidelity International Ltd | 2024-06-30 | 2.1 M | Ark Investment Management Llc | 2024-09-30 | 1.5 M | Fmr Inc | 2024-09-30 | 1.5 M | Vanguard Group Inc | 2024-09-30 | 11.7 M | Blackrock Inc | 2024-06-30 | 11.2 M |
Guardant Health Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Guardant Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Guardant Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Guardant Health insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Guardant Health Outstanding Bonds
Guardant Health issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Guardant Health uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Guardant bonds can be classified according to their maturity, which is the date when Guardant Health has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| US40139LAG86 Corp BondUS40139LAG86 | View | |
| GUARDN 3246 29 MAR 27 Corp BondUS40139LBF94 | View | |
| GUARDN 555 28 OCT 27 Corp BondUS40139LBG77 | View | |
| US40139LBC63 Corp BondUS40139LBC63 | View | |
| GUARDN 125 13 MAY 26 Corp BondUS40139LBD47 | View | |
| GUARDN 1625 16 SEP 28 Corp BondUS40139LBE20 | View |
Guardant Health Corporate Filings
F4 | 19th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 13th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 6th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 29th of October 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
Currently Active Assets on Macroaxis
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.28) | Revenue Per Share 5.7 | Quarterly Revenue Growth 0.339 | Return On Assets (0.16) | Return On Equity (6.09) |
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Guardant Health's value and its price as these two are different measures arrived at by different means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.